Sign up
Pharma Capital

C4X Discovery preparing to do something 'very different' in drug development

Clive Dix, chief executive of C4X Discovery Holdings plc, (LON:C4XD) brings Proactive up to speed on developments with the firm's portfolio of drug candidates.

They've recently presented some pre-clinical data at a leading industry conference which they say strengthens the evidence base backing the potential of the anti-addiction drug Orexin-1.

It's being developed to target the craving process and therefore is expected to be used across a broad range of substance disorders.

The latest study assessed nicotine self-administration and cue-induced reinstatement; the latter is where strong cravings are triggered by an object or ritual closely associated with taking an addictive substance.


View full C4XD profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.